1. Home
  2. UHG vs PLRX Comparison

UHG vs PLRX Comparison

Compare UHG & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Homes Group Inc

UHG

United Homes Group Inc

HOLD

Current Price

$1.19

Market Cap

68.8M

ML Signal

HOLD

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

HOLD

Current Price

$1.30

Market Cap

81.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHG
PLRX
Founded
N/A
2015
Country
United States
United States
Employees
195
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
81.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
UHG
PLRX
Price
$1.19
$1.30
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
$2.67
AVG Volume (30 Days)
79.1K
415.1K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.97
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$1.09
52 Week High
$4.78
$1.95

Technical Indicators

Market Signals
Indicator
UHG
PLRX
Relative Strength Index (RSI) 40.93 51.16
Support Level $1.15 $1.12
Resistance Level $1.81 $1.36
Average True Range (ATR) 0.02 0.07
MACD 0.02 -0.00
Stochastic Oscillator 77.78 68.75

Price Performance

Historical Comparison
UHG
PLRX

About UHG United Homes Group Inc

United Homes Group Inc designs, builds and sells homes in high growth markets, including South Carolina, North Carolina, and Georgia. UHG employs a land-light operating, with a focus on the design, construction and sale of entry-level, first, second and third move-up single-family houses. The company principally builds detached single-family houses, and, to a lesser extent, attached single-family houses, including duplex houses and town houses. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Share on Social Networks: